Reshaping the future of patient care
ECOG-ACRIN BY THE NUMBERS
Loading Quotes...
News and Announcements
NCI-MATCH trial enrolling an average of 7-8 new patients weekly; positive findings from substudy Y presented, read press release
President, American Society of Hematology
Martin S. Tallman, MD
Hematologic Oncologist and Chief, Leukemia Service
Memorial Sloan Kettering Cancer Center
Congratulations to Dr. Tallman, who chaired the ECOG-ACRIN Leukemia Committee for 16 years. Dr. Tallman will serve a one-year term as vice president of ASH, starting in December, followed by successive terms as president-elect and president.
We acknowledge Dr. Tallman for his tremendous leadership of the Leukemia Committee during his tenure from 1997-2013. Practice-changing studies in AML and other acute and chronic leukemias occurred during this time, and he greatly enhanced the scientific structure that supports the committee’s activities to this day.
Achievement Award in Medicine
Edith Peterson Mitchell
Brigadier General USAF (Retired), MD, FACP, FCPP
Clinical Professor of Medicine and Medical Oncology
Thomas Jefferson University
Congratulations to Dr. Mitchell, a long-standing member of ECOG-ACRIN and a national champion for health equity in cancer clinical trials, for this recognition. The award honors a Jefferson physician who has embraced Jefferson’s mission, provided exemplary care to their patients, and has been a recognized leader in their field.
Meet the 2018 Young Investigator Symposium presenters here
The E2112 study recently reached its enrollment goal! Learn more about the trial for men and women with advanced breast cancer, here
Results of TAILORx released, read press release
Results of NCI-MATCH (EAY131) Arms I, Q, and W released, read press release
Webinar on patient-reported outcomes research by David Cella, PhD, available here
New Trials in 2018
October 3, 2018
Pembrolizumab and Dasatinib, Imatinib Mesylate, or Nilotinib in Treating Patients with Chronic Myeloid Leukemia and Persistently Detectable Minimal Residual Disease
October 1, 2018
Pembrolizumab Compared to Standard of Care Observation in Treating Patients With Completely Resected Stage I-III Merkel Cell Cancer
July 23, 2018
Understanding and Predicting Breast Cancer Events after Treatment (the UPBEAT trial)
UPBEAT (WF97415) trial info coming soon
July 9, 2018
Multiparametric MRI (mpMRI) for Preoperative Staging and Treatment Planning for Newly-Diagnosed Prostate Cancer
May 17, 2018
Financial Burden Assessment in Patients with Stage I-III Colon or Rectal Cancer Undergoing Treatment
May 2, 2018
Cisplatin / Carboplatin and Etoposide with or without Nivolumab in Treating Patients with Extensive Stage Lung Cancer
April 26, 2018
Venetoclax and Vincristine Liposomal in Treating Patients With Relapsed or Refractory T-cell or B-cell Acute Lymphoblastic Leukemia
April 13, 2018
Nivolumab after Combined Modality Therapy in Treating Patients with High Risk Stage II-IIIB Anal Cancer
April 5, 2018
Osimertinib in Treating Patients with Stage IIIB-IV or Recurrent Non-small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations
March 28, 2018
Chemotherapy Before Surgery and Radiation Therapy or Surgery and Radiation Therapy Alone in Treating Patients With Nasal and Paranasal Sinus Cancer That Can Be Removed by Surgery
March 1, 2018
Nivolumab, Cabozantinib S-Malate, and Ipilimumab in Treating Patients With Recurrent Stage IV Non-small Cell Lung Cancer
February 14, 2018
Computed Tomography Perfusion Imaging in Predicting Outcomes in Patients with Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Receiving Bevacizumab and Paclitaxel
February 8, 2018
Abiraterone Acetate and Antiandrogen Therapy with or without Cabazitaxel and Prednisone in Treating Patients with Metastatic, Hormone-Sensitive Prostate Cancer Previously Treated with Docetaxel
EA8153 (CHAARTED2) trial info here
© 2018 ECOG-ACRIN Cancer Research Group. All rights reserved. | Disclaimer